Jpmorgan Chase & CO Exagen Inc. Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Exagen Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 35 shares of XGN stock, worth $109. This represents 0.0% of its overall portfolio holdings.
Number of Shares
35
Previous 34
2.94%
Holding current value
$109
Previous $0
NaN%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding XGN
# of Institutions
37Shares Held
6.29MCall Options Held
2.5KPut Options Held
200-
Rtw Investments, LP New York, NY1.51MShares$4.75 Million0.05% of portfolio
-
Cowen And Company, LLC891KShares$2.8 Million0.04% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT762KShares$2.39 Million0.01% of portfolio
-
Silvercrest Asset Management Group LLC New York, NY545KShares$1.71 Million0.01% of portfolio
-
Perkins Capital Management Inc493KShares$1.55 Million0.88% of portfolio
About EXAGEN INC.
- Ticker XGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 16,260,400
- Market Cap $51.1M
- Description
- Exagen Inc. develops and commercializes various testing products based on its cell-bound complement activation products technology under the AVISE brand in the United States. It enables rheumatologists to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus ery...